missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Lipofectamine™ CRISPRMAX™ Cas9 Transfection Reagent
The first optimized lipid nanoparticle transfection reagent for CRISPR-Cas9 protein delivery.
Brand: Invitrogen™ CMAX00001
81.81 EUR valid until 2024-12-31
Use promo code "21651" to get your promotional price.
This item is not returnable.
View return policy
Description
- Demonstrated cleavage efficiency—tested in over 20 cell types including iPSC, mESC, N2A, CHO, A549, HCT116, HeLa, HEK293, and several others
- Low cell toxicity—less cells needed to initiate your experiment
- High throughput friendly—an ideal delivery solution for 96-well format
- Lipofectamine CRISPRMAX transfection reagent increases the likelihood of successful cleavage and recombination, especially when combined with our TrueCut Cas9 Protein v2 and TrueGuide Synthetic gRNA.
- Unlike CRISPR plasmid or Cas9 mRNA, using Cas9 protein provides superior cleavage efficiency in primary cells and stem cells.
- It eliminates the need for transcription or translation of the payload, removes the risk of genomic integration, and is cell cycle independent.
Specifications
Animal Origin-Free | |
Established Cell Lines, Stem Cells, Primary Cells, Hard-to-Transfect Cells | |
Protein, Ribonucleoprotein, Cas9 Ribonucleoprotein, Cas9, Plasmid DNA | |
Transfection | |
Transfection Reagent | |
Yes |
Contains one vial of Lipofectamine CRISPRMAX Reagent and one vial of Cas9 Plus Reagent. Store at 2–8°C. Do not freeze. |
|
6-well Plate, 12-well Plate, 24-well Plate, 48-well Plate, 96-well Plate, Flasks | |
Lipid-based Transfection | |
CRISPRMAX™, Lipofectamine™ | |
0.1 mL | |
Approved for shipment at Room Temperature or on Wet Ice |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Invitrogen™ Lipofectamine™ CRISPRMAX™ Cas9 Transfection Reagent > 0.1 mL
For Research Use Only. Not for use in diagnostic procedures.
Spot an opportunity for improvement?Share a Content Correction